Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Matthew H. G. Katz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3870-6968; OpenAlex author ID A5011254389, A5152861078; NIH RePORTER profile ID 9837084. Sources: ClinicalTrials.gov.

Their work

Papers
249 (first author 32, last author 42)
Trials
5 (principal investigator on 4)
Grants
1
Labs led
1
Collaborators
585
Papers, trials and grants by year

2011: 3 papers · 2012: 19 papers · 2013: 9 papers · 2014: 12 papers · 2015: 16 papers, 1 trial · 2016: 15 papers, 1 trial · 2017: 17 papers, 1 trial · 2018: 14 papers · 2019: 26 papers, 1 grant · 2020: 14 papers, 1 trial · 2021: 26 papers, 1 trial · 2022: 17 papers · 2023: 15 papers · 2024: 17 papers · 2025: 10 papers · 2026: 19 papers

Papers 50 of 249

  1. Top advances of the year: Neoadjuvant therapy in pancreatic cancer. First author DOI 10.1002/cncr.70431↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  5. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  6. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  7. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002608↗
  8. Clinicopathologic Characteristics of Brain Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000002470↗
  9. Preventing Futile Laparotomy in Pancreatic Cancer through Selective Multimodal Staging. First author DOI 10.1097/sla.0000000000007108↗
  10. A Word of Caution: Operation Alone Remains Inadequate for Pancreatic Cancer. First author DOI 10.1097/xcs.0000000000001735↗
  11. Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4733↗
  12. Exercise Modulates Microbial Metabolites and Induces Stromal Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-5143↗
  13. Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States. Co-author DOI 10.1200/op-25-00351↗
  14. Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Do… Co-author DOI 10.1200/op-25-01431↗
  15. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  16. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18691-x↗
  17. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18865-7↗
  18. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  19. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  20. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  21. Discovering signature disease trajectories in pancreatic cancer and soft-tissue sarcoma from longitudinal patient records. Co-author DOI 10.1016/j.jbi.2025.104935↗
  22. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  23. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  24. Fatty pancreas on EUS: Risk factors, correlation with CT/MRI, and implications for pancreatic cancer screening. Co-author DOI 10.1097/eus.0000000000000109↗
  25. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  26. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  27. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  28. The Landmark Series: The Future of Pancreatic Cancer Clinical Trials. First author DOI 10.1245/s10434-024-16840-2↗
  29. The Landmark Series: Neoadjuvant Therapy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17736-5↗
  30. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  31. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00464-024-11022-3↗
  32. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  33. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  34. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… Co-author DOI 10.1093/bjs/znae033↗
  35. Response to: Comment on "Effects of a Pragmatic Home-Based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreati… Last author DOI 10.1097/as9.0000000000000435↗
  36. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  37. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  38. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  39. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  40. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  41. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  42. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Co-author DOI 10.1245/s10434-023-14815-3↗
  43. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A02150… Last author DOI 10.1245/s10434-024-15670-6↗
  44. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  45. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  46. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. First author DOI 10.3390/cancers16193312↗
  47. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply. Co-author DOI 10.1001/jamaoncol.2022.6147↗
  48. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Last author DOI 10.1002/jhbp.1218↗
  49. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05534-3↗
  50. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗

Trials 5

  1. An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiati… Principal investigator NCT05056805↗
  2. Assessment of What Patients and Healthcare Providers Value Principal investigator NCT04483349↗
  3. PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer Principal investigator NCT03187951↗
  4. Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer Study chair NCT02839343↗
  5. Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer Principal investigator NCT02295956↗

Grants 1

  1. PancFit: Do angiogenic biomarkers correlate with improved progression free survival in pancreatic cancer? R21CA218732↗

Closest collaborators

The 25 strongest of 585 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ching-Wei David Tzeng · 76 shared papers, 2012–2026 · strength 10.37
  2. Laura R. Prakash · 61 shared papers, 2015–2026 · strength 8.58
  3. Michael P. Kim · 60 shared papers, 2015–2026 · strength 7.67
  4. Jeffrey E. Lee · 89 shared papers, 2011–2026 · strength 7.49
  5. Robert A. Wolff · 74 shared papers, 2011–2026 · strength 6.19
  6. Naruhiko Ikoma · 34 shared papers, 2020–2026 · strength 5.63
  7. Anirban Maitra · 59 shared papers, 2014–2026 · strength 5.62
  8. Eugene Jon Koay · 46 shared papers, 2014–2026 · strength 5.03
  9. Rebecca Anne Snyder · 20 shared papers, 2016–2026 · strength 4.75
  10. Huamin Wang · 58 shared papers, 2012–2026 · strength 4.27
  11. Gauri Rajani Varadhachary · 65 shared papers, 2011–2023 · strength 3.98
  12. Jason B. Fleming · 79 shared papers, 2011–2022 · strength 3.79
  13. Marc G. Besselink · 17 shared papers, 2019–2026 · strength 3.13
  14. Eileen Mary O'Reilly · 14 shared papers, 2017–2026 · strength 2.80
  15. Bas Groot Koerkamp · 14 shared papers, 2019–2026 · strength 2.69
  16. Shubham Pant · 19 shared papers, 2019–2026 · strength 2.52
  17. Joseph M. Herman · 20 shared papers, 2013–2026 · strength 2.31
  18. Amer H. Zureikat · 11 shared papers, 2022–2026 · strength 2.25
  19. Alice Chia-Chi Wei · 11 shared papers, 2022–2026 · strength 2.25
  20. Nathan H. Parker · 18 shared papers, 2014–2026 · strength 2.17
  21. An Ngo‐Huang · 15 shared papers, 1 shared grant, 2015–2026 · strength 2.13
  22. Michael James Overman · 21 shared papers, 2013–2026 · strength 2.06
  23. David R. Fogelman · 28 shared papers, 2012–2021 · strength 1.90
  24. Milind M. Javle · 28 shared papers, 2011–2023 · strength 1.88
  25. Dan Zhao · 10 shared papers, 2023–2026 · strength 1.82

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.